Karen Chong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen Chong has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
David Chitayat
Division of Clinical and Metabolic Genetics Department of Paediatrics The Hospital for Sick Children University of Toronto Toronto Ontario Canada
4 shared publications- David Chitayat
The Prenatal Diagnosis and Medical Genetics Program, Department of Obstetrics and Gynecology, Mount Sinai Hospital University of Toronto Toronto Ontario Canada
4 shared publications Patrick Shannon
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
3 shared publications- Abdul Noor
Affiliations Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada, University of Toronto, Toronto, Ontario, Canada
2 shared publications Ants Toi
Department of Medical Imaging, Mount Sinai Hospital, Toronto, ON, Canada
2 shared publicationsChristian Marshall
Department of Laboratory Medicine and Pathobiology University of Toronto Toronto Ontario Canada
2 shared publications
Latest Publications
- Open Access
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 422-431
Monogenic conditions and central nervous system anomalies: A prospective study, systematic review and meta‐analysis
Objectives: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G‐banding karyotype in fetuses with central nervous system (CNS) abnormalities.Methods: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random‐effects model.Results: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%–36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%–34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%–23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%–40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%–57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X‐linked hydrocephalus.Conclusions: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 422-431
Open AccessMonogenic conditions and central nervous system anomalies: A prospective study, systematic review and meta‐analysis
Objectives: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G‐banding karyotype in fetuses with central nervous system (CNS) abnormalities.Methods: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random‐effects model.Results: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%–36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%–34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%–23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%–40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%–57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X‐linked hydrocephalus.Conclusions: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.
- 28 January 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (7) , 822-830
Diagnostic yield of genome sequencing for prenatal diagnosis of fetal structural anomalies
Objective: Genome sequencing (GS >30x) is beginning to be adopted as a comprehensive genome‐wide test for the diagnosis of rare disease in the post‐natal setting. Recent studies demonstrated the utility of exome sequencing (ES) in prenatal diagnosis, we investigate the potential benefits for GS to act as a comprehensive prenatal test for diagnosis of fetal abnormalities.Methods: We performed GS on a prospective cohort of 37 singleton fetuses with ultrasound‐identified structural abnormalities undergoing invasive prenatal testing. GS was performed in parallel with standard diagnostic testing, and the prioritized variants were classified according to ACMG guidelines and reviewed by a panel of board‐certified laboratory and clinical geneticists.Results: Diagnostic sequence variants were identified in 5 fetuses (14%), with pathogenic variants found in NIPBL, FOXF1, RERE, AMMECR1, and FLT4. A further 7 fetuses (19%) had variants of uncertain significance (VUS) that may explain the phenotypes. Importantly, GS also identified all pathogenic variants reported by clinical microarray (2 CNVs, 5%).Conclusion: Prenatal GS offered diagnoses (sequence variants and CNVs) in 19% of fetuses with structural anomalies. GS has the potential of replacing multiple consecutive tests, including microarray, gene panels, and WES, to provide the most comprehensive analysis in a timely manner necessary for prenatal diagnosis.
- 28 January 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (7) , 822-830
Diagnostic yield of genome sequencing for prenatal diagnosis of fetal structural anomalies
Objective: Genome sequencing (GS >30x) is beginning to be adopted as a comprehensive genome‐wide test for the diagnosis of rare disease in the post‐natal setting. Recent studies demonstrated the utility of exome sequencing (ES) in prenatal diagnosis, we investigate the potential benefits for GS to act as a comprehensive prenatal test for diagnosis of fetal abnormalities.Methods: We performed GS on a prospective cohort of 37 singleton fetuses with ultrasound‐identified structural abnormalities undergoing invasive prenatal testing. GS was performed in parallel with standard diagnostic testing, and the prioritized variants were classified according to ACMG guidelines and reviewed by a panel of board‐certified laboratory and clinical geneticists.Results: Diagnostic sequence variants were identified in 5 fetuses (14%), with pathogenic variants found in NIPBL, FOXF1, RERE, AMMECR1, and FLT4. A further 7 fetuses (19%) had variants of uncertain significance (VUS) that may explain the phenotypes. Importantly, GS also identified all pathogenic variants reported by clinical microarray (2 CNVs, 5%).Conclusion: Prenatal GS offered diagnoses (sequence variants and CNVs) in 19% of fetuses with structural anomalies. GS has the potential of replacing multiple consecutive tests, including microarray, gene panels, and WES, to provide the most comprehensive analysis in a timely manner necessary for prenatal diagnosis.
- 22 May 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 55 (3) , 383-390
Microarray and RASopathy‐disorder testing in fetuses with increased nuchal translucency
Objectives: To determine the incidence of chromosomal abnormalities, submicroscopic chromosomal abnormalities and RASopathy‐disorder (RD) pathogenic variants in a cohort of pregnancies with nuchal translucency thickness (NT) ≥ 3.5 mm, and to propose a clinical protocol for surveillance of this group of patients.Methods: This was a retrospective chart review of patients referred to The Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital between January 2013 and December 2015, due to NT ≥ 3.5 mm, who underwent chorionic villus sampling or amniocentesis. Patients underwent extensive genetic counseling prior to invasive procedures and testing. Quantitative fluorescence polymerase chain reaction (QF‐PCR) was performed as the first‐line test for aneuploidy. If the result was negative, patients underwent karyotyping and/or chromosomal microarray analysis (CMA), and if the findings were normal, they had testing for RD pathogenic variants, which included nine known genes. Patients also underwent detailed fetal ultrasound examinations and echocardiography, performed by expert operators.Results: A total of 226 eligible patients were identified. In 116/226 (51.3%) patients, QF‐PCR identified a chromosomal aneuploidy. The remaining 110/226 (48.7%) patients had further genetic testing. Karyotyping/CMA detected an abnormal/pathogenic cytogenetic result in 9/110 (8.2%) patients, as well as five variants of unknown significance (VOUS). RD testing yielded three pathogenic variants (3/103), giving a detection rate of 2.9%, and one VOUS. The optimal NT cut‐off for RD screening was 7.9 mm in this population. In 92/110 (83.6%) patients, the genetic investigations were normal. Of these pregnancies, an early (14–16 weeks' gestation) detailed fetal ultrasound examination identified a structural abnormality in 24 (26.1%), 15 (16.3%) had an abnormal detailed ultrasound examination at 18–22 weeks' gestation and fetal echocardiography showed a cardiac abnormality in nine (9.8%). The birth outcome in the 83 pregnancies that had normal genetic investigations and known outcome included seven (8.4%) cases of termination of pregnancy, seven (8.4%) cases of intrauterine fetal death and 69 (83.1%) cases of live birth. Nine (9.8%) patients were lost to follow‐up.Conclusions: Both CMA and molecular testing for RD are important investigations in pregnancies with NT ≥ 3.5 mm. The use of genetic testing combined with fetal ultrasound examination provides valuable information that can influence pregnancy outcome, and provide recurrence risks, in this patient population. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
- 22 May 2019
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 55 (3) , 383-390
Microarray and RASopathy‐disorder testing in fetuses with increased nuchal translucency
Objectives: To determine the incidence of chromosomal abnormalities, submicroscopic chromosomal abnormalities and RASopathy‐disorder (RD) pathogenic variants in a cohort of pregnancies with nuchal translucency thickness (NT) ≥ 3.5 mm, and to propose a clinical protocol for surveillance of this group of patients.Methods: This was a retrospective chart review of patients referred to The Prenatal Diagnosis and Medical Genetics Program at Mount Sinai Hospital between January 2013 and December 2015, due to NT ≥ 3.5 mm, who underwent chorionic villus sampling or amniocentesis. Patients underwent extensive genetic counseling prior to invasive procedures and testing. Quantitative fluorescence polymerase chain reaction (QF‐PCR) was performed as the first‐line test for aneuploidy. If the result was negative, patients underwent karyotyping and/or chromosomal microarray analysis (CMA), and if the findings were normal, they had testing for RD pathogenic variants, which included nine known genes. Patients also underwent detailed fetal ultrasound examinations and echocardiography, performed by expert operators.Results: A total of 226 eligible patients were identified. In 116/226 (51.3%) patients, QF‐PCR identified a chromosomal aneuploidy. The remaining 110/226 (48.7%) patients had further genetic testing. Karyotyping/CMA detected an abnormal/pathogenic cytogenetic result in 9/110 (8.2%) patients, as well as five variants of unknown significance (VOUS). RD testing yielded three pathogenic variants (3/103), giving a detection rate of 2.9%, and one VOUS. The optimal NT cut‐off for RD screening was 7.9 mm in this population. In 92/110 (83.6%) patients, the genetic investigations were normal. Of these pregnancies, an early (14–16 weeks' gestation) detailed fetal ultrasound examination identified a structural abnormality in 24 (26.1%), 15 (16.3%) had an abnormal detailed ultrasound examination at 18–22 weeks' gestation and fetal echocardiography showed a cardiac abnormality in nine (9.8%). The birth outcome in the 83 pregnancies that had normal genetic investigations and known outcome included seven (8.4%) cases of termination of pregnancy, seven (8.4%) cases of intrauterine fetal death and 69 (83.1%) cases of live birth. Nine (9.8%) patients were lost to follow‐up.Conclusions: Both CMA and molecular testing for RD are important investigations in pregnancies with NT ≥ 3.5 mm. The use of genetic testing combined with fetal ultrasound examination provides valuable information that can influence pregnancy outcome, and provide recurrence risks, in this patient population. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
- 16 January 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 39 (9) , 693-700
Prenatal detection of isolated bilateral hyperechogenic kidneys: Etiologies and outcomes
Objectives: To delineate the etiology and outcome of prenatally diagnosed isolated bilateral hyperechogenic kidneys (IBHK).Study Design: Pregnancies with IBHK on prenatal ultrasound identified and followed by us between January 1, 2000 and January 1, 2015 were evaluated regarding the etiology and outcome by evaluation of family history, targeted AR‐PKD and AD‐PKD DNA analysis, and microarray analysis, according to renal size and amniotic fluid volume.Results: Of the 52 identified cases, there were 34 cases with enlarged kidneys, 16 with normal size kidneys, and two with small kidneys. There were seven cases with AD‐PKD, six inherited, and one with de novo causative variants in the PKD1 gene. Fifteen had AR‐PKD, and microarray analysis showed two inherited findings: one with 17q12 deletion including the HNF1B/TCF2 gene inherited from asymptomatic mother and a duplication at 3p26.1 inherited from a healthy father. Of the remaining four cases, three cases had bilateral multicystic dysplastic kidneys, and one had unilateral renal agenesis.Conclusion: Microarray analysis and mutation analysis for PKD1 and PKHD1 have an important contribution to the diagnostic investigation of IBHK and to the management of affected and future pregnancies. Poor outcome was associated with large hyperechoic kidneys with oligohydramnios.
- 16 January 2019
- Published by Wiley in Prenatal Diagnosis
- Vol. 39 (9) , 693-700
Prenatal detection of isolated bilateral hyperechogenic kidneys: Etiologies and outcomes
Objectives: To delineate the etiology and outcome of prenatally diagnosed isolated bilateral hyperechogenic kidneys (IBHK).Study Design: Pregnancies with IBHK on prenatal ultrasound identified and followed by us between January 1, 2000 and January 1, 2015 were evaluated regarding the etiology and outcome by evaluation of family history, targeted AR‐PKD and AD‐PKD DNA analysis, and microarray analysis, according to renal size and amniotic fluid volume.Results: Of the 52 identified cases, there were 34 cases with enlarged kidneys, 16 with normal size kidneys, and two with small kidneys. There were seven cases with AD‐PKD, six inherited, and one with de novo causative variants in the PKD1 gene. Fifteen had AR‐PKD, and microarray analysis showed two inherited findings: one with 17q12 deletion including the HNF1B/TCF2 gene inherited from asymptomatic mother and a duplication at 3p26.1 inherited from a healthy father. Of the remaining four cases, three cases had bilateral multicystic dysplastic kidneys, and one had unilateral renal agenesis.Conclusion: Microarray analysis and mutation analysis for PKD1 and PKHD1 have an important contribution to the diagnostic investigation of IBHK and to the management of affected and future pregnancies. Poor outcome was associated with large hyperechoic kidneys with oligohydramnios.
- 24 January 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (2) , 117-122
Nonisolated diaphragmatic hernia in Simpson‐Golabi‐Behmel syndrome
Objective: Congenital diaphragmatic hernia (CDH) is associated with Simpson‐Golabi‐Behmel syndrome (SGBS), but few cases diagnosed prenatally have been reported. The aim of this series is to highlight the association of nonisolated CDH with SGBS type I on prenatal ultrasound and emphasize the importance of genetic testing, fetal autopsy, and family history in confirming this diagnosis.Method: Retrospective review of 3 cases of SGBS type I in a single tertiary care centre. Family history, fetal ultrasound, autopsy findings, and genetic testing for GPC3 was performed for each case.Results: Fetal ultrasound findings in the second trimester were CDH, omphalocele, increased nuchal fold, renal anomaly, and cleft lip and palate. Fetal autopsy confirmed the prenatal ultrasound findings and also showed dysmorphic facial features and premalignant lesions on renal and gonadal histology. Microarray and DNA analysis of the GPC3 gene confirmed the diagnosis of SGBS type I in each case.Conclusion: Nonisolated CDH in a male fetus suggests a diagnosis of SGBS type I. Fetal autopsy, pedigree analysis, and genetic testing for GPC3 are all essential to confirming the diagnosis. The histological findings of ovotestes and nephroblastomatosis indicate that cancer predisposition is established early in fetal life.
- 24 January 2018
- Published by Wiley in Prenatal Diagnosis
- Vol. 38 (2) , 117-122
Nonisolated diaphragmatic hernia in Simpson‐Golabi‐Behmel syndrome
Objective: Congenital diaphragmatic hernia (CDH) is associated with Simpson‐Golabi‐Behmel syndrome (SGBS), but few cases diagnosed prenatally have been reported. The aim of this series is to highlight the association of nonisolated CDH with SGBS type I on prenatal ultrasound and emphasize the importance of genetic testing, fetal autopsy, and family history in confirming this diagnosis.Method: Retrospective review of 3 cases of SGBS type I in a single tertiary care centre. Family history, fetal ultrasound, autopsy findings, and genetic testing for GPC3 was performed for each case.Results: Fetal ultrasound findings in the second trimester were CDH, omphalocele, increased nuchal fold, renal anomaly, and cleft lip and palate. Fetal autopsy confirmed the prenatal ultrasound findings and also showed dysmorphic facial features and premalignant lesions on renal and gonadal histology. Microarray and DNA analysis of the GPC3 gene confirmed the diagnosis of SGBS type I in each case.Conclusion: Nonisolated CDH in a male fetus suggests a diagnosis of SGBS type I. Fetal autopsy, pedigree analysis, and genetic testing for GPC3 are all essential to confirming the diagnosis. The histological findings of ovotestes and nephroblastomatosis indicate that cancer predisposition is established early in fetal life.
- Open Access
- 20 July 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (9) , 1435-1437
Severe phenotype of X‐linked dominant chondrodysplasia punctata
Key Clinical Message: A prenatally ascertained case representing the more severe end of the X‐linked dominant chondrodysplasia punctata (CDPX2).
- 20 July 2017
- Published by Wiley in Clinical Case Reports
- Vol. 5 (9) , 1435-1437
Open AccessSevere phenotype of X‐linked dominant chondrodysplasia punctata
Key Clinical Message: A prenatally ascertained case representing the more severe end of the X‐linked dominant chondrodysplasia punctata (CDPX2).
- 1 November 2015
- Published by BMJ in Journal of Medical Genetics
- Vol. 52 (Suppl 2) , A2.2-A2
MG-104 Fetal jugular lymph sacs – what is the significance?: Abstract MG-104 Table 1
Fetal jugular lymph sacs are accumulations of lymphatic fluid in the anterolateral region of the fetal neck. They may be isolated or occur in association with other structural anomalies and in some cases are presenting with an increased nuchal translucency or cystic hygroma. Their significance and the guidelines for the prenatal investigation when identified in the course of routine ultrasonography in pregnancy are still controversial. Our protocol for the investigation of these cases includes microarray analysis and DNA analysis for the Noonan syndrome panel. We report our experience with ten cases of prenatally diagnosed isolated fetal jugular neck cysts identified in the last 5 years (Table 1). Cases of isolated fetal jugular neck cysts In 10 cases identified by us in the last 5 years, 50% had a pathogenic mutation in a Noonan syndrome Panel, one had trisomy 21 and none had abnormality on microarray analysis (in the case with T21 we stopped the analysis following the QF-PCR results). However, all cases with abnormal results had NT > 3.5 mm or cystic hygroma. This study suggests that the identification of fetal jugular lymph sacs with an increased NT/cystic hygroma is associated with an increased incidence of Noonan syndrome and its related disorders and should instigate mutation analysis of the Noonan syndrome panel.
- 1 November 2015
- Published by BMJ in Journal of Medical Genetics
- Vol. 52 (Suppl 2) , A2.2-A2
MG-104 Fetal jugular lymph sacs – what is the significance?: Abstract MG-104 Table 1
Fetal jugular lymph sacs are accumulations of lymphatic fluid in the anterolateral region of the fetal neck. They may be isolated or occur in association with other structural anomalies and in some cases are presenting with an increased nuchal translucency or cystic hygroma. Their significance and the guidelines for the prenatal investigation when identified in the course of routine ultrasonography in pregnancy are still controversial. Our protocol for the investigation of these cases includes microarray analysis and DNA analysis for the Noonan syndrome panel. We report our experience with ten cases of prenatally diagnosed isolated fetal jugular neck cysts identified in the last 5 years (Table 1). Cases of isolated fetal jugular neck cysts In 10 cases identified by us in the last 5 years, 50% had a pathogenic mutation in a Noonan syndrome Panel, one had trisomy 21 and none had abnormality on microarray analysis (in the case with T21 we stopped the analysis following the QF-PCR results). However, all cases with abnormal results had NT > 3.5 mm or cystic hygroma. This study suggests that the identification of fetal jugular lymph sacs with an increased NT/cystic hygroma is associated with an increased incidence of Noonan syndrome and its related disorders and should instigate mutation analysis of the Noonan syndrome panel.
- 1 April 2015
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 41 (4) , S130
2083329 The Outcome of Isolated Blake’s Pouch Cyst Causing Rotation of The Vermis
- 1 April 2015
- Published by Elsevier in Ultrasound in Medicine & Biology
- Vol. 41 (4) , S130
2083329 The Outcome of Isolated Blake’s Pouch Cyst Causing Rotation of The Vermis
- 4 June 2014
- Published by Taylor & Francis in Systems Biology in Reproductive Medicine
- Vol. 60 (6) , 377-382
PGD for a carrier of an intrachromosomal insertion using aCGH
Intrachromosomal insertions are rare and difficult to diagnose. However, making the correct diagnosis is critical for genetic risk assessment, and prenatal and preimplantation genetic diagnosis outcomes. We present a case of preimplantation genetic diagnosis (PGD) using array comparative genomic hybridization (aCGH) following trophectoderm biopsy of embryos created after in vitro fertilization for a carrier of an intrachromosomal insertion on chromosome 1 [46,XX, ins(1)(q44q23q32.1)]. The PGD analysis of 6 blastocysts demonstrated 67% unbalanced embryos. No pregnancy was achieved after the transfer of 2 euploid embryos. To the best of our knowledge, this is the first reported case of PGD using aCGH following trophectoderm biopsy for a carrier of an intrachromosomal insertion.
- 4 June 2014
- Published by Taylor & Francis in Systems Biology in Reproductive Medicine
- Vol. 60 (6) , 377-382
PGD for a carrier of an intrachromosomal insertion using aCGH
Intrachromosomal insertions are rare and difficult to diagnose. However, making the correct diagnosis is critical for genetic risk assessment, and prenatal and preimplantation genetic diagnosis outcomes. We present a case of preimplantation genetic diagnosis (PGD) using array comparative genomic hybridization (aCGH) following trophectoderm biopsy of embryos created after in vitro fertilization for a carrier of an intrachromosomal insertion on chromosome 1 [46,XX, ins(1)(q44q23q32.1)]. The PGD analysis of 6 blastocysts demonstrated 67% unbalanced embryos. No pregnancy was achieved after the transfer of 2 euploid embryos. To the best of our knowledge, this is the first reported case of PGD using aCGH following trophectoderm biopsy for a carrier of an intrachromosomal insertion.
- Open Access
- 23 May 2012
- Published by Wiley in Prenatal Diagnosis
- Vol. 32 (6) , 611
Referral patterns for microarray testing in prenatal diagnosis
- 23 May 2012
- Published by Wiley in Prenatal Diagnosis
- Vol. 32 (6) , 611
Open AccessReferral patterns for microarray testing in prenatal diagnosis